PerturbAI Unveils The Largest In Vivo CRISPR Atlas For Drug Discovery

PerturbAI Emerges from Stealth with a Game-Changing CRISPR Atlas

In a groundbreaking development, PerturbAI, a pioneering AI-native therapeutics company, has revealed the world's largest in vivo CRISPR atlas. This impressive dataset, encompassing eight million brain-wide cells, positions PerturbAI at the forefront of drug discovery innovation. The company’s new platform, named Perturb-seq, enables in-depth measurements of gene functions within intact biological systems, distinguishing it from traditional methods that often focus on isolated cell states.

With this public unveiling, PerturbAI underscores a pivotal shift in the biological sciences. "The public release of this CRISPR atlas marks a foundational change for biology," stated Dr. Xin Jin, co-founder of PerturbAI. By providing a scalable and comprehensive view of gene function directly within living tissues, the atlas paves the way for a more nuanced understanding of diseases and therapeutic strategies. The ability to simulate and model potential interventions before large-scale clinical trials can significantly reduce both time and cost in drug development.

This achievement was made possible through collaboration with leading organizations, including NVIDIA, the Allen Institute for Brain Science, and 10x Genomics. The resultant dataset not only emphasizes the complexity of genetic interactions across different neuronal cell types but also reveals that the same gene can yield varying effects based on cell type and broader biological context.

Dr. Grace Zheng, co-founder and CEO of PerturbAI, emphasized the importance of leveraging both in vivo CRISPR technology and advanced AI to unlock cutting-edge therapeutic potentials for challenging metabolic and chronic diseases. The combinative expertise of the team, spanning genomics, CRISPR technology, and machine learning, uniquely positions PerturbAI to optimize drug discovery processes.

The initiation of this dataset's analysis highlights the systematic evaluation of the brain genome, allowing researchers to differentiate between causal genomic mechanisms and modifiers that influence disease progression. Such insights could drastically accelerate the development of biological foundation models, as the atlas serves as a rich resource for AI training across diverse cellular contexts.

The release of the associated manuscript titled "Genome-scale functional mapping of the mammalian whole brain with in vivo Perturb-seq" signals an academic milestone, with further access provided through PerturbAI’s blog, Hugging Face, and the NVIDIA AI Blueprint for Single-Cell Analysis.

This pivotal contribution to genomics exemplifies PerturbAI's commitment to enhancing drug discovery through sophisticated technology and a deeper biological understanding. Investors have already taken note, as demonstrated by the overwhelming success of PerturbAI's recent pre-seed funding round, attributed to early-stage investors who specialize in AI and biology.

As PerturbAI continues to innovate within the therapeutic landscape, it embodies a forward-thinking approach that merges advancements in AI with life sciences, setting a new standard in how we understand and address complex health conditions moving forward.

For more information about PerturbAI and its revolutionary work in therapeutics, visit www.perturb.ai.